Gianfranco De Feo

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial

Emanuela Rossi, Alessandro Morabito, Francesca Di Rella et al. · Journal of Clinical Oncology · 2009 · 80 citations

Tamoxifen Result, Hormonal Contraceptive, Breast Oncology +19

Clinical trials and drug cost savings for Italian health service

Francesca D’Ambrosio, Gianfranco De Feo, Gerardo Botti et al. · BMC Health Services Research · 2020 · 32 citations · Full text

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

Francesco Nuzzo, Ciro Gallo, Secondo Lastoria et al. · Annals of Oncology · 2012 · 29 citations · Full text

Bone Disease, Breast Oncology, Bone Health +11

Time Spent for Activation of Non-Profit Studies in Oncology in Italy

Gianfranco De Feo, Simona Signoriello, Jane Bryce et al. · PLoS ONE · 2010 · 23 citations · Full text